千金药业(600479) - 2025 Q4 - 年度业绩

Financial Performance - Total operating revenue for 2025 reached ¥3,634,578,070.78, a slight increase of 0.13% compared to ¥3,629,804,492.14 in the previous year[4] - Operating profit rose to ¥440,507,648.01, marking a significant increase of 32.64% from ¥332,110,652.19 year-on-year[4] - Net profit attributable to shareholders was ¥287,836,838.39, reflecting a growth of 24.74% compared to ¥230,756,619.25 in the prior year[4] - The company reported a net profit excluding non-recurring gains and losses of ¥261,435,059.34, a 19.48% increase from ¥218,815,693.34[4] Asset and Equity Growth - Total assets increased by 10.71% to ¥5,044,504,252.10 from ¥4,556,298,077.73 at the beginning of the period[4] - Shareholders' equity attributable to the parent company rose by 23.06% to ¥3,030,178,541.36 from ¥2,462,279,280.07[4] Earnings and Returns - Basic earnings per share improved to ¥0.6414, an increase of 14.97% from ¥0.5579[4] - The weighted average return on net assets increased to 9.73%, up by 0.19 percentage points from 9.54%[4] Acquisitions - The company acquired 28.92% of Hunan Qianjin Xiangjiang Pharmaceutical Co., Ltd. and 68% of Hunan Qianjin Xieli Pharmaceutical Co., Ltd., which began contributing to consolidated results in October and November 2025, respectively[5] Risk Advisory - The company advises investors to be aware of potential risks as the reported financial data is preliminary and subject to change in the final annual report[6]